Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
ID: 341374Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $600K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/341374

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-173.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at facilitating the development of well-planned clinical trials in cancer prevention and control. This program seeks to address critical information gaps that often arise during the planning phase of clinical trials, focusing on enhancing areas such as cancer-related health behaviors, screening, early detection, and supportive care for cancer survivors. Eligible applicants include a diverse range of institutions, including tribal governments and historically black colleges, with funding available up to $600,000 for projects that include pilot trials over a maximum period of three years. Interested parties should note that the application deadline is September 7, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-173-Full-Announcement.html
    PAR-22-173.html
    The Department of Health and Human Services, through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34). This program aims to support the development of well-planned clinical trials in cancer prevention and control areas to effectively enhance capabilities in areas such as cancer-related health behaviors, screening, early detection, and supportive care for survivors. The goal is to address information gaps that typically arise during the trial planning phase, which can impede the completion and rigor of clinical trials. Applications for this funding opportunity must focus on activities necessary to enrich the protocol of a full-scale clinical trial, addressing specific planning issues such as study population identification, recruitment strategies, and intervention testing. Eligible applicants include various institutions, nonprofits, and tribal governments, with funding up to $225,000 per year for projects without clinical trials, and up to $600,000 for those that include a pilot trial over a maximum period of three years. Multiple opportunities for applications exist, reinforcing NCI's commitment to innovative research strategies to improve cancer outcomes. The proposal process involves critical adherence to specific guidelines to ensure compliance and successful submission.
    Similar Opportunities
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at supporting the planning of clinical trials that enhance cancer prevention, detection, and survivorship. This program seeks to address critical gaps in preliminary data, participant recruitment strategies, and study designs necessary for finalizing trial protocols, thereby facilitating effective cancer intervention trials aligned with public health goals. Eligible organizations, including higher education institutions and nonprofits, can apply for funding of up to $225,000 per year for a maximum of three years, with a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. Interested applicants should note the open submission date of January 25, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating the planning of clinical trials that enhance cancer prevention, intervention, and survivor care. This program seeks to address critical information gaps that hinder effective trial protocols, including population characteristics and operational risks, by requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams and participant recruitment. With funding of up to $225,000 per year available for planning initiatives, eligible organizations include higher education institutions, non-profits, and tribal governments, with a project period of up to three years. Interested applicants should note the submission deadline of January 25, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing cancer burdens through advancements in early detection, prevention, and healthcare delivery. This funding opportunity, identified as PAR-25-167, specifically excludes trials focused on cancer diagnosis or oncologic therapies in patients, emphasizing the importance of improving public health and clinical practices related to cancer. Eligible applicants include a wide range of organizations, such as academic institutions, non-profits, and tribal governments, with applications due by February 5, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-167.html.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)," aimed at accelerating the development of evidence-based cancer interventions that address health disparities among diverse populations in the United States. This initiative will support research that tests the impact of cancer-related interventions on outcomes through a pragmatic trial design, structured in two phases: the UG3 phase for preparatory activities and intervention refinement, followed by the UH3 phase for conducting the trial. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with funding amounts capped at $500,000 for the UG3 phase and $750,000 for the UH3 phase. Interested parties should note that applications are due by November 17, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.